Fosnetupitant
Akynzeo (fosnetupitant) is a small molecule pharmaceutical. Fosnetupitant was first approved as Akynzeo on 2018-04-19.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Akynzeo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fosnetupitant chloride hydrochloride
+
Palonosetron hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AKYNZEO | Helsinn Healthcare | N-210493 RX | 2020-05-27 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| akynzeo | New Drug Application | 2023-12-10 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Fosnetupitant Chloride Hydrochloride / Palonosetron Hydrochloride, Akynzeo, Helsinn Hlthcare | |||
| 10624911 | 2037-06-02 | DP | |
| 11529362 | 2037-06-02 | DP | |
| 8426450 | 2032-05-23 | DS, DP | |
| 8895586 | 2032-05-23 | U-2301 | |
| 9403772 | 2032-05-23 | DP | U-2301 |
| 9908907 | 2032-05-23 | DS, DP | |
| 10208073 | 2032-05-23 | U-2301 | |
| 10717721 | 2032-05-23 | DP | |
| 11312698 | 2032-05-23 | DS, DP | |
| 10828297 | 2030-12-17 | U-2301 | |
| 9186357 | 2030-11-18 | U-2301 | |
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg |
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nausea | D009325 | HP_0002018 | R11.0 | — | 6 | 7 | — | 1 | 13 |
| Neoplasms | D009369 | — | C80 | — | 2 | 1 | — | 1 | 3 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | 1 | 1 | — | — | 1 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | 1 | 1 | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Sarcoma | D012509 | — | — | — | — | — | — | 1 | 1 |
| Stomatitis | D013280 | EFO_1001904 | K12.1 | — | — | — | — | 1 | 1 |
| Lymphoma | D008223 | — | C85.9 | — | — | — | — | 1 | 1 |
| Neuroblastoma | D009447 | EFO_0000621 | — | — | — | — | — | 1 | 1 |
| Central nervous system neoplasms | D016543 | — | — | — | — | — | — | 1 | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | — | — | 1 | 1 |
| Chordoma | D002817 | EFO_0000334 | — | — | — | — | — | 1 | 1 |
| Nervous system neoplasms | D009423 | — | — | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fosnetupitant |
| INN | fosnetupitant |
| Description | Fosnetupitant is a medication used for the treatment of chemotherapy-induced nausea and vomiting. It is a prodrug of netupitant. It is used in combination with palonosetron hydrochloride and formulated as the salt fosnetupitant chloride hydrochloride for intravenous use.
|
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1703748-89-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989917 |
| ChEBI ID | — |
| PubChem CID | 71544786 |
| DrugBank | DB14019 |
| UNII ID | T672P80L2S (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 102 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
386 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use